Korro Bio, Inc. Interest Expense
Korro Bio, Inc. (KRRO) reported Interest Expense of $0 for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2023-11-02
- Korro Bio, Inc. interest expense for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Korro Bio, Inc. interest expense for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Korro Bio, Inc. interest expense for the quarter ending 2023-03-31 was $284.00K, a 59.55% increase year-over-year.
- Korro Bio, Inc. interest expense for the quarter ending 2022-12-31 was $312.00K, a 71.43% increase year-over-year.
- Korro Bio, Inc. interest expense for fiscal 2022 was $961.00K, a 25.79% increase from fiscal 2021.
- Korro Bio, Inc. interest expense for fiscal 2021 was $764.00K.
- Korro Bio, Inc. interest expense for fiscal 2020 was $0.00.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $284.00K 10-Q · filed 2023-11-02 | $596.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | $284.00K 10-Q · filed 2023-08-10 | $596.00K derived: sum of 3 quarters · filed 2023-08-10 | $859.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-03-31 | $284.00K 10-Q · filed 2023-05-12 | $596.00K derived: sum of 2 quarters · filed 2023-05-12 | $859.00K derived: sum of 3 quarters · filed 2023-11-02 | $1.07M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-12-31 | $312.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $575.00K derived: sum of 2 quarters · filed 2023-11-02 | $783.00K derived: sum of 3 quarters · filed 2023-11-02 | $961.00K 10-K · filed 2023-03-10 |
| 2022-09-30 | $263.00K 10-Q · filed 2023-11-02 | $471.00K derived: sum of 2 quarters · filed 2023-11-02 | $649.00K 10-Q · filed 2023-11-02 | $831.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $208.00K 10-Q · filed 2023-08-10 | $386.00K 10-Q · filed 2023-08-10 | $568.00K derived: sum of 3 quarters · filed 2023-08-10 | $750.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $178.00K 10-Q · filed 2023-05-12 | $360.00K derived: sum of 2 quarters · filed 2023-05-12 | $542.00K derived: sum of 3 quarters · filed 2023-05-12 | $724.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $182.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $364.00K derived: sum of 2 quarters · filed 2023-03-10 | $546.00K derived: sum of 3 quarters · filed 2023-03-10 | $764.00K 10-K · filed 2023-03-10 |
| 2021-09-30 | $182.00K 10-Q · filed 2022-11-08 | $364.00K derived: sum of 2 quarters · filed 2022-11-08 | $582.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $182.00K 10-Q · filed 2022-08-09 | $400.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $218.00K 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-15 | |||
| 2018-09-30 | $63.00K 10-Q · filed 2019-11-18 | $95.00K 10-Q · filed 2019-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |